CD25/IL-2R alpha Antibody (daclizumab) [Biotin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28337B
Recombinant Monoclonal Antibody
![Novus Antibodies Novus Antibodies](https://resources.rndsystems.com/categoryimages/novus_antibodies.jpg)
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Biotin
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # daclizumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
IL-2Ra / CD25
Reactivity Notes
Predicted species reactivity: Mouse, Rat, Rhesus
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for CD25/IL-2R alpha Antibody (daclizumab) [Biotin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD25/IL-2R alpha
Long Name
Interleukin 2 Receptor alpha
Alternate Names
CD25, IL-2 R alpha, IL-2Ra, IL2R alpha, IL2RA
Gene Symbol
IL2RA
Additional CD25/IL-2R alpha Products
Product Documents for CD25/IL-2R alpha Antibody (daclizumab) [Biotin]
Product Specific Notices for CD25/IL-2R alpha Antibody (daclizumab) [Biotin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...